BeiGene Ltd (HK:6160) has released an update.
BeiGene Ltd. has expanded its board of directors from 11 to 12 members with the appointment of Ms. Shalini Sharp as an independent non-executive director and member of the audit committee, effective September 27, 2024. Ms. Sharp’s extensive experience in the biopharmaceutical industry and financial expertise, highlighted by her previous roles and educational background, is expected to contribute significantly to the company’s diversity and governance. The company has expressed a warm welcome to Ms. Sharp, who will receive compensation in line with the company’s existing policy for independent directors.
For further insights into HK:6160 stock, check out TipRanks’ Stock Analysis page.
